Compositions and methods for transdermal delivery of hormones and other medicinal agents

A transdermal delivery system, comprising a backing layer affixed to an adhesive polymer matrix, wherein the adhesive polymer matrix comprises:

• a. about 3.5% (w/w) to about 4% (w/w) of a first penetration enhancer selected from the group consisting of levulinic acid and a pharmaceutically acceptable salt thereof;
• b. about 2.2% (w/w) to about 2.8% (w/w) of a second penetration enhancer that is glyceryl monooleate;
• c. about 86% (w/w) to about 90% (w/w) of an adhesive polymer that is a random copolymer of 2-ethylhexyl acrylate and vinyl acetate;
• d. about 2% (w/w) to about 4% (w/w) of a humectant that is a copolymer of vinylpyrrolidone and vinyl acetate;
• e. about 0.7% (w/w) to about 0.9% (w/w) levonorgestrel;
• and
• f. about 0.7% (w/w) to about 0.9% (w/w) ethinyl estradiol.

A transdermal delivery system, comprising a backing layer affixed to an adhesive polymer matrix, wherein the adhesive polymer matrix comprises:

• a. about 3.5% (w/w) to about 4% (w/w) levulinic acid;
• b. about 6% (w/w) to about 9% (w/w) lauryl lactate;
• c. about 80% (w/w) to about 88% (w/w) of an adhesive polymer that is an acrylate-vinylacetate copolymer;
• d. about 2% (w/w) to about 4% (w/w) of a humectant that is a copolymer of vinylpyrrolidone and vinyl acetate;
• e. about 0.7% (w/w) to about 0.9% (w/w) levonorgestrel;
• and
• f. about 0.7% (w/w) to about 0.9% (w/w) ethinyl estradiol.